Multi-Cancer Detection Test for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests blood-based multi-cancer detection (MCD) tests to evaluate their effectiveness in screening for various cancers before symptoms appear. Participants will join one of three groups: two groups will receive different MCD tests, and one will serve as a control group. The study aims to determine the effectiveness of these tests in early cancer detection and their impact on decisions regarding further care. Individuals aged 45-75, without a cancer diagnosis in the last five years, and who can provide blood samples may be suitable for this trial. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research in early cancer detection.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study demonstrated that the Avantect Multi-Cancer Detection Test is a simple blood test designed to screen healthy individuals for cancer. It has been certified in the UK, indicating its safety and reliability. Research on the Shield Multi-Cancer Detection Test shows it is highly accurate in detecting cancer, with a 98.6% specificity rate, meaning it effectively identifies individuals without cancer. Both tests require a blood sample, a common and low-risk procedure.
As these tests are part of a study without a specific phase, safety is likely still under close monitoring. However, the Shield test has received FDA Breakthrough Device Designation, suggesting it showed promise in effectiveness and safety in earlier evaluations. Overall, these tests are non-invasive, generally easy to tolerate, and have few side effects.12345Why are researchers excited about this trial?
Researchers are excited about these multi-cancer detection tests because they offer a revolutionary approach to early cancer detection. Traditional cancer screening methods often focus on specific cancers and may require invasive procedures, but the Avantect and Shield MCD tests use a simple blood draw to screen for multiple cancers at once. This non-invasive technique could potentially catch cancer earlier than conventional methods, which generally target single types of cancer and often involve more complex procedures. By providing the possibility of early detection across various cancer types, these tests have the potential to significantly improve outcomes for patients and reduce the need for more invasive diagnostic methods.
What evidence suggests that this trial's multi-cancer detection tests could be effective for cancer screening?
In this trial, participants will join different arms to evaluate the effectiveness of two Multi-Cancer Detection (MCD) tests. Research has shown that the Avantect MCD test can detect several types of cancer by identifying specific markers in the blood, aiding in early cancer detection when treatment is most effective. Participants in one arm will undergo the Avantect MCD test. Meanwhile, the Shield MCD test, administered to participants in another arm, demonstrated a 98.5% accuracy in identifying individuals without cancer and a 60% success rate in detecting existing cancers. For the six most aggressive cancers, Shield's success rate increases to 74%. Both tests aim to detect cancer early, potentially leading to better treatment outcomes.16789
Who Is on the Research Team?
Scott D Ramsey
Principal Investigator
Fred Hutchinson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults aged 45-75 who can consent and complete questionnaires in English, Spanish, or Arabic. Participants must agree to give blood samples for MCD testing at the start and one year later, and allow access to their medical records.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Enrollment and Baseline Testing
Participants undergo blood collection for MCD testing at enrollment
Intervention
Participants undergo MCD testing and receive results; follow-up with clinicians for abnormal results
Follow-up
Participants are monitored for safety and effectiveness after intervention
What Are the Treatments Tested in This Trial?
Interventions
- Multi-Cancer Detection Test
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor